Free Trial

Novacyt (NCYT) Competitors

Novacyt logo
GBX 39 -1.60 (-3.94%)
As of 12:00 PM Eastern

NCYT vs. EKF, CREO, IUG, POLX, IHC, AVO, MHC, RUA, SUN, and BELL

Should you be buying Novacyt stock or one of its competitors? The main competitors of Novacyt include EKF Diagnostics (EKF), Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), MyHealthChecked (MHC), RUA Life Sciences (RUA), Surgical Innovations Group (SUN), and Belluscura (BELL). These companies are all part of the "medical devices" industry.

Novacyt vs.

EKF Diagnostics (LON:EKF) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, community ranking, media sentiment and valuation.

EKF Diagnostics has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Novacyt has a beta of -1.86, meaning that its share price is 286% less volatile than the S&P 500.

EKF Diagnostics received 291 more outperform votes than Novacyt when rated by MarketBeat users. Likewise, 76.76% of users gave EKF Diagnostics an outperform vote while only 58.06% of users gave Novacyt an outperform vote.

CompanyUnderperformOutperform
EKF DiagnosticsOutperform Votes
327
76.76%
Underperform Votes
99
23.24%
NovacytOutperform Votes
36
58.06%
Underperform Votes
26
41.94%

EKF Diagnostics has higher revenue and earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£49.91M1.88£4.68M£1.0719.64
Novacyt£18.12M1.49-£36.80M-£54.44-0.72

In the previous week, Novacyt had 1 more articles in the media than EKF Diagnostics. MarketBeat recorded 1 mentions for Novacyt and 0 mentions for EKF Diagnostics. Novacyt's average media sentiment score of 1.53 beat EKF Diagnostics' score of 0.67 indicating that Novacyt is being referred to more favorably in the news media.

Company Overall Sentiment
EKF Diagnostics Positive
Novacyt Very Positive

70.3% of EKF Diagnostics shares are held by institutional investors. Comparatively, 0.1% of Novacyt shares are held by institutional investors. 5.2% of EKF Diagnostics shares are held by insiders. Comparatively, 3.1% of Novacyt shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

EKF Diagnostics has a net margin of 9.37% compared to Novacyt's net margin of -203.06%. EKF Diagnostics' return on equity of 7.03% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics9.37% 7.03% 5.27%
Novacyt -203.06%-47.73%-27.98%

Summary

EKF Diagnostics beats Novacyt on 13 of the 15 factors compared between the two stocks.

Remove Ads
Get Novacyt News Delivered to You Automatically

Sign up to receive the latest news and ratings for NCYT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NCYT vs. The Competition

MetricNovacytMedical Devices IndustryMedical SectorLON Exchange
Market Cap£26.95M£3.34B£5.24B£2.41B
Dividend YieldN/A2.44%4.87%4.95%
P/E Ratio-0.7275.5621.20127.76
Price / Sales1.49122.32356.35257,920.01
Price / Cash0.5815.9938.1627.87
Price / Book0.393.636.234.33
Net Income-£36.80M£126.02M£3.20B£5.76B
7 Day Performance-6.15%-4.85%-8.32%2.04%
1 Month Performance-19.25%-5.82%-3.36%0.73%
1 Year Performance-9.30%-13.15%2.72%92.67%

Novacyt Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NCYT
Novacyt
N/AGBX 39
-3.9%
N/A-9.6%£26.95M£18.12M-0.72120Positive News
Gap Down
EKF
EKF Diagnostics
N/AGBX 22.11
-4.9%
N/A-18.3%£98.28M£49.91M20.58356
CREO
Creo Medical Group
N/AGBX 13
-1.0%
N/A-67.4%£52.56M£33.87M-2.06279News Coverage
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57M-18.9165
POLX
Polarean Imaging
N/AGBX 1.12
-0.9%
N/A-76.4%£16.37M£5.21M-0.2928
IHC
Inspiration Healthcare Group
N/AGBX 16.60
-0.9%
N/A-42.8%£14.38M£42.87M-1.14224Positive News
Gap Down
AVO
Advanced Oncotherapy
N/AN/AN/AN/A£9.50MN/A-25.003,900Gap Down
MHC
MyHealthChecked
N/AGBX 15.40
+1.0%
N/A+24.4%£8.01M£9.43M-7.6816
RUA
RUA Life Sciences
N/AGBX 11.88
-1.0%
N/A+27.1%£7.37M£4.05M-2.7748
SUN
Surgical Innovations Group
N/AGBX 0.57
+2.7%
N/A+14.0%£5.27M£12.54M-21.1180Gap Up
BELL
Belluscura
N/AGBX 1.50
-4.8%
N/A-86.3%£3.78M£2.87M-0.1624Gap Up
High Trading Volume
Remove Ads

Related Companies and Tools


This page (LON:NCYT) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners